Member Info for ROCKZ

Haha Hundal, 4 of those names have disappeared!

This is exactly why Gabrielle is not going to let Accustem go on the cheap.
I see people time and again commenting on this board that Accustem is going to be sold before coming to market but I just can’t see it, I think they are wrong.
GC will be on a personal mission to extract maximum value from Accustem and he has the data to back it up. The current $280 million valuation will be laughable in the not too distant future.
As will the current market cap of Tiziana.

Strictlyinc, I wouldn’t be concerned, I think you and many others here have played a blinder.
It will re-align again at some point and no doubt surpass TILS.
Only a gut feeling but I think this could be when Biden takes over from our orange friend.

Although Tiziana and Accustem are now separate entities, I believe the rising SP of TILS can only benefit Accustem.
Success breeds success and investor confidence in the board of directors will have increased, especially the way they have started the New Year.
Upon the rise of TILS during the summer we also saw considerable gains for OKYO pharma who also have the same BOD as TILS.

I seem to remember Jadam sold before the surge.
Maybe around the £1.40 mark from memory although I still think he bagged.
Manabouttown seemed to disappear after TILS hit £2.60! I’m guessing he did pretty well and moved on.
Fairly quiet on the BB at the moment. You generally get a feel that once these relentless posters arrive the SP starts to move north.

Pete, I take your point but the trial was obviously pushed through in order for the company to glean enough information and confidence to then programme a Phase 2b trial with the correct number of participants.

No single company is going to get the monopoly on producing their treatment, MABS are not as easy to produce as some drugs and the results of MABS are looking impressive.
This is a worldwide problem and various companies/treatments will provide us with a way out of this pandemic.
Tiziana is very well placed and the stars could very well align for the company. It hasn’t just happened overnight for them, they have been developing Foralumab and TZLS-501 for years and it really could be a case of ‘right place, right time’.

Treatments alongside ongoing vaccinations will be the only way out of this worldwide crisis now.
Tiziana, with its novel form of nasal administration has an advantage over competitors due to the fact it’s MAB’s are cheaper to produce, less doseage required along with less toxicity.
Price will become an important factor in distributing this worldwide.

Phase 2b. A larger trial.

I’ve got the feeling we’re in for an interesting afternoon with both markets open.

Good to see Stims. It looks like the company have taken on somebody to run the social media account.
A social media presence is a must for a listed multi million pound company these days.
A strong start to the new year from the BOD.

Great RNS, great new proactive video with Dr Howard Weiner.
Well done to the BOD.
Well done me, managed to get an early morning top up, 1591 @ 93.5p.
I think our friends across the pond will enjoy this news and that video.

Cloudy, I agree that would be a perfect scenario if the hospital used for the trial in Sao Paulo were to continue using Foralumab on compassionate grounds.

I think we will see an RNS this week in relation to the Brazil trial data. The BOD have stated early January and if the news is positive they will be keen to get it out there and strike while the irons hot.
If the PR is right, the Tiziana company name will be well out there in the mainstream media both sides of the pond and the SP will be hard to suppress. I can see it going north of £2 and we may even see a return to that mad summer Friday when it went out of control and maybe challenge £3.
The move to the main market on 21st January will be well timed, encourage further buying from more risk adverse investors and should help stabilise the SP without the volatility that we see on the AIM.
Hopefully the transition to the main market will knock the US automatic bots out of sync for a while!
If the Brazil data is good, I’m expecting a raise will be required which Gabrielle confirmed if the SP is at a decent level. The last raise of £57 million has the company fully cashed for the next couple of years but this is excluding positive Brazil trial data which will then mean further trials and development need accelerating.
The company would have to go down this route and remain pro active although we may see a tie up with a larger pharmaceutical company or even a takeover approach.
AIMO. If the Brazil data is average, time to hunker down for a few weeks/months hold tight and forget about the SP for a while! So much other potential in the pipeline if this shot doesn’t work, exciting times ahead. Happy new year.

Yes originally they said we should have the results this side of Christmas but on the investors call GC confirmed the trial will have finished this year but we won’t get the data until early Jan.
I think it’s a good strategy, people are pre-occupied this time of year.
New wave of confidence and all systems go fo 2021.

During the investors conference call GC confirmed that the Brazil trial data would be available in early January.
He also confirmed that we can expect more analyst reports within the next 3 months.

Merry Christmas everyone. Looking forward to January. Excited to be involved with this company. Hopefully a monster in the making. Good luck all.

Another woeful day for Hurricane shareholders. I actually expected it to turn around, thought we had already seen the bottom but this share never fails to disappoint in disappointment!

Please elaborate Alwaysone? You’ve been in and out of this stock for a while now so should have decent knowledge of the company. Tell us more...

I think most of us who invested in TILS/ACCUSTEM accepted there would be some sort of raise at some point for ACCUSTEM, no surprises.
Since the announcement of StemprintER, many have speculated on their theory of a buy out and some would have invested on this basis.
The BOD have always been transparent with their vision for Accustem and GC was very positive about it on the conference call.